The Undruggables
By Megan Scudellari The Undruggables Can young biotechs chasing elusive drug targets succeed where so many have failed? They think so. G-protein coupled receptors in the cell membrane Courtesy of Anchor Therapeutics and Arkitek Studios John Andrews finished his presentation and turned to the roomful of pharmaceutical employees. Chief scientific officer for NeurAxon, a small Canadian biotech developing pain therapeutics, Andrews braced himself for the o
Nov 1, 2010
The Undruggables
Can young biotechs chasing elusive drug targets succeed where so many have failed? They think so.

John Andrews finished his presentation and turned to the roomful of pharmaceutical employees. Chief scientific officer for NeurAxon, a small Canadian biotech developing pain therapeutics, Andrews braced himself for the onslaught. The comments came rapid-fire: Can it be produced efficiently? Yes, in just a few steps. It is really soluble? It has been from day one. Is it truly selective? Yes.
Interested in reading more?

Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?